20190082
PhilipsResearchPHILIPSthe
Mar01,2019
ClinicalStudyInvestigation Plan
PJ-011726 Studytoestablish thepsychometric
properties ofthedigitalcognitive testsonthe
PhilipsIntelliSpace Cognition Platform
Document history
Version: Date: Author: Description/Change/Reason forChange
0.1 09-08-2017LauraKiaming, 1stversionBenSchmand
0.2 24-08-2017 DaisyvanMinde2ndversion
0.3 07-03-2018 LauraKiaming, RonDotsch3d1version
0.4 18-09-2018LauraKiaming, 4thversionBenSchmand
0.5 04-10-2018DaisyvanMinde, 5thversionMurrayGillies
RonDotsch,BenSchmand,
0.6 07-11-2018 JamesHoidnack, Justin 6thversion
Miller,DaisyvanMinde
0.7 14-11-2018 MandySpaltman Newtemplate andfewadditions
0.8 16-11-2018 DaisyvanMinde 8thversion
0.9 29-11-2018 DaisyvanMinde 9thversion
MinorchangesafterICBEsecretary0.10 06-12-2018 MandySpaltmanreview
0.11 13-12-2018 MandySpaitman MinorchangesafterICBEreview
Comments afterpre-review ICBEand
0.12 14-12-2018 DaisyvanMinde fromQ&Raddressed.
FinaldraftbeforeICBEBoardreview
Addeddefinition ‘normdata’tochapter
0.13 19-12-2018 Gert-Jan Adriaans 3asitisthemainpurposeofstudyand
reflecting toprivacyassesment.
0.14 19-12-2018 MandySpaitman Slightrephrasing ofnormdatadefinition.
1.0 21-12-2018 MandySpaitman Removing markupforapproved version.
Title:ClinicalInvestigation Plan Author:LauraKlaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version: 2.0 Date:2019-02-18 Status:Approved Page: 1of35
IRBMANAGER PI[INVESTIGATOR_8571] —QIPROJECT
PhilipsResearchP11 ILIPS
2.0 18-02-2019 MandySpaitman Edittooursamplesize.
APPROVAL /PROTOCOL SIGNATURE [CONTACT_232085] !Date
(yyyy-mmm-dd)
Regulatory Representative ofSponsor MartaWalker
Sr.Q&RManager Philips HealthWorks,
Business Excellence
Principal Investigator [INVESTIGATOR_231996] (i.Umcid
2O1-O3-Z
Title:Clinical Investigation Plan Author: LauraKlaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version: 2.0 Date:2019-02-18 Status: Approved Page:2of35
IRBMANAGER PI[INVESTIGATOR_8571]—QI PROJECT
PhilipsResearch
PHILIPS
ROLES/RESPONSIBILITIES
Thissectioncontains alistofallpartiesandpersons involved intheClinicalInvestigation.
Coordinating
investigator!
ProjectleaderDaisyvanMinde
HighTechCampus 34.1.038
5656AEEindhoven, theNetherlands
Tel:[PHONE_4868]
Email:[EMAIL_4524]
JamesHoldnack
5RoseHillDrive,BearDE19701
Principal investigator(s) U.S.A
Tel:+[PHONE_4866]
Email:iames.ho1dnackphi1ips.com
Investigational Site N/A
Otherparticipating sitesSeveralofficeroomswillberentedinthe[LOCATION_003]toconductthestudy.
Sponsor (theindividual
ororganization taking PhilipsElectronics Nederland B.V.,
responsibility and actingthrough itsPhilipsHealthWorks organization
liabilityfortheinitiation HighTechCampus 34
orimplementation ofa5656AEEindhoven, TheNetherlands
clinicalinvestigation)
Subsidizing party N/A
Independent
physician(s) N/A
(theNetherlands only)**
Laboratory sites N/A
Co-investigators
.RoelCuppen —SeniorArchitect
.MandySpaltman —Psychologist Researcher
.GijsvanElswijk —Cognitive Scientist
.RonDotch —Cognitive Psychologist! Datascientist
.StefanVermeent -Psychologist! Datascientist
.BenSchmand —Professor inClinicalNeuropsychology
Appendix
.A.Sampling plan
.B.Validation ISC —devicelist
Title:ClinicalInvestigation Plan Author:LauraKlaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version:2.0 Date:2019-02-18jStatus:Approved Page:3of35
IRBMANAGER PI[INVESTIGATOR_8571] —QIPROJECT
PhilipsResearchP1—IILIPS
TABLEOFCONTENTS
APPROVAL! PROTOCOL SIGNATURE [CONTACT_106127] 2
ROLES/RESPONSIBILITIES 3
TABLEOFCONTENTS 4
LISTOFABBREVIATIONS ANDRELEVANT DEFINITIONS 5
11EXECUTIVE SUMMARY 7
2INVESTIGATIONAL DEVICE 14
2.1DeviceSummary 14
2.2Intended purpose 16
2.3DeviceDescription 16
3JUSTIFICATION 16
4RISKSANDBENEFITS ASSESSMENT 19
Ihavecreatedanduploaded ariskmanagement summary matrix 19
5OBJECTIVES ANDHYPOTHESES 20
6CLINICAL INVESTIGATION DESIGN 21
6.1General 21
6.2Investigational device(s) andcomparator(s) 23
6.3Subjects 23
6.4Procedures 24
Specimen Banking (savinghumanfluidortissueforfutureresearch) 24
6.5Monitoring plan 25
7STATISTICAL CONSIDERATIONS 25
8DATAMANAGEMENT 27
9AMENDMENTS 28
10DEVIATIONS 28
11DEVICEACCOUNTABILITY 29
12STATEMENTS OFCOMPLIANCE 29
13INFORMED CONSENT PROCESS 30
14ADVERSE EVENTS ANDDEVICE DEFICIENCIES 30
15INVESTIGATOR BROCHURE (IB) 33
16VULNERABLE POPULATION 33
Title:clinicalInvestigation Plan Author:LauraKlaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version: 2.0 Date:2019-02-18 Status:Approved Page:4of35
IRBMANAGER PI[INVESTIGATOR_8571] —QIPROJECT
PhilipsResearchP1—IILIPS
17SUSPENSION ORPREMATURE TERMINATION 33
18PUBLICATION POLICY 34
19BIBLIOGRAPHY 34
LISTOFABBREVIATIONS ANDRELEVANT DEFINITIONS
ABR ABRform,GeneralAssessment andRegistration form,istheapplication formrequired forsubmission to
theaccredited EthicsCommittee
InDutch,ABR=Algemene Beoordeling enRegistratie
AE Adverse Event
Anyuntoward medicaloccurrence, unintended diseaseorinjury,oruntoward clinicalsigns(including
abnormal laboratory findings) insubjects, usersorotherpersons,whetherornotrelatedtothe
investigational medicaldevice
AR Adverse Reaction
CA Competent Authority
Clinical Systematic investigation inoneormoresubjects, undertaken toassessthesafetyandperformance ofa
Investigation medicaldevice
CIP ClinicalInvestigation Plan
Document thatstate(s)therationale, objectives, designandproposed analysis, methodology, monitoring,
conductandrecord-keepi[INVESTIGATOR_231997]:Thetermprotocol” issynonymous withCIP”.However, protocolhasmanydifferentmeanings,
somenotrelatedtoclinicalinvestigation, andthesecandifferfromcountrytocountry.
CFA Confirmatory factoranalyses
CFR CodeofFederalRegulations
CNS CentralNervous System
COWAT Controlled OralWordAssocation Test
CRF CaseReportForm
Setofprinted,opticalorelectronic documents foreachsubjectonwhichinformation tobereported tothe
sponsor isrecorded, asrequired by[CONTACT_232017],
EDC Electronic Database Capture
Endpoint Principal indicator(s) usedforassessing theprimaryhypothesis ofaclinicalinvestigation
EU European Union
FDA FoodandDrugAdministration
GCP GoodClinicalPractice
HCP HealthCare Professional
HSDP HealthSuite DigitalPlatform (Philips)
Hypothesis Testable statement, resulting fromtheobjective, regarding theinvestigational medicaldevicesafetyor
performance usedtodesigntheclinicalinvestigation andthatcanbeaccepted orrejectedbasedonresults
oftheclinicalinvestigation andstatistical calculations.
NOTE:Theprimaryhypothesis isthedeterminant oftheinvestigational medicaldevicesafetyor
performance parameters andisusuallyusedtocalculate thesamplesize.Secondary hypotheses
concerning otherpointsofinterestcanalsobeevaluated.
ADL ActivityofDailyLiving
lB Investigator’s Brochure
IC Informed Consent
Theinformed consent isdocumented by[CONTACT_232018],signedanddatedinformed consentform.
Theinformed consentprocess istheprocessby[CONTACT_232019].
ID Identification
IRB Institutional ReviewBoard
ISC IntelliSpace Cognition
Title:ClinicalInvestigation Plan Author:LauraKlaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version: 2.0 Date:2019-02-18 Status:Approved Page:5of35
IRBMANAGER PI[INVESTIGATOR_8571] —QIPROJECT
PhilipsResearchP1—IILIPS
Investigator Individual member oftheinvestigation siteteamdesignated andsupervised by[CONTACT_232020]-investigation-related procedures ortomakeimportant clinical
investigation- relateddecisions.
NOTE:Anindividual member oftheinvestigation siteteamcanalsobecalled“sub-investigator” or“co
investigator”.
MMSE-[ADDRESS_279962]
SAE SeriousAdverse Event
Adverseeventthat
a)ledtodeath,
b)ledtoseriousdeterioration inthehealthofthesubject,thateitherresulted in
1)alife-threatening illnessorinjury,or
2)apermanent impairment ofabodystructure orabodyfunction, or
3)in-patient orprolonged hospi[INVESTIGATOR_059], or
4)medicalorsurgicalintervention topreventlife-threatening illnessorinjuryorpermanent
impairment toabodystructure orabodyfunction,
c)ledtofoetaldistress, foetaldeathoracongenital abnormality orbirthdefect
NOTEPlanned hospi[INVESTIGATOR_231998]-existing condition, oraprocedure required by[CONTACT_232021],without
seriousdeterioration inhealth,isnotconsidered aseriousadverseevent.
Sponsor Individual ororganization takingresponsibility andliabilityfortheinitiation orimplementation ofaclinical
investigation
TBI Traumatic BrainInjury
TMT TrailMakingTest
[LOCATION_003] UnitedStatesofAmerica
Title:ClinicalInvestigation Plan Author:LauraKlaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version: 2.0 Date:2019-02-18 Status:Approved Page:6of35
IRBMANAGER PI[INVESTIGATOR_8571] —QIPROJECT
PhilipsResearchP11ILIPS
11EXECUTIVE SUMMARY
StudyTitle&ID PJ-011726Psychometric properties ofIntelliSpace Cognition
Fulltitle:Studytoestablish thepsychometric properties ofthe
digitalcognitive testsonthePhilipsIntelliSpace Cognition
Platform
. N/AProjectName
. ThisstudyaimstovalidatetheteststhatareontheIntelliSpaceBriefSummary ofStudyCognition platformandtoestablish normative dataforthesetests.
Providealay-language abstractof
yourstudyplan(100-300 words)
. Cognitive modelKeyWordsAssociated with
StudyCognitive assessment
Digitalcognitive tests
Provide 3-5PubMed MeSHAutomated scoringkeywordsAlgorithms
Country(s) fromwherethe1Netherlands [LOCATION_003] El[LOCATION_013] LiChina
dataoriginates (where LIIndia LiBelgium LI[LOCATION_006] LIKenya
collected) LIOther:
Thisstudywillbeconducted pertherequirements ofISO
[ZIP_CODE]
ThisstudyWILLNOTbeconducted pertherequirements of
ISO14155.Forexample studiesformerly knownasH-liteand
J-Lite
Thisstudyhasnoclinicalprimaryorsecondary objectives.
However thedatagenerated fromthisstudywillbeusedas
grounddatainaDeviceclassIlaccording toregulation CFR21
ISO14155compliance Sec.882.1470 Computerized cognitive assessment aid.
Therefore PhilipswillfollowISO14155,GoodClinicalPractice in
allapplicable requirements.
Datagenerated fromthistrialwillbemonitored andwillbePart11
compliant.
Important note1:Therearenoforeseeable risksorpossible
adverseeventsinthisstudy.Thisisanon-significant riskstudy.
Thestudywillbesubmitted tolOBEandIRBreview/approval.
Isthisstudypartofa No
studentprojectlthesis? LIYes,StudentName: [CONTACT_33710]:
Primaryobjective Thestudyhasfouraims.
Title:ClinicalInvestigation Plan Author:LauraKlaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version:2.0 Date:2019-02-18 Status:Approved Page:7of35
IRBMANAGER PI[INVESTIGATOR_8571]—01PROJECT
PhilipsResearchP11ILIPS
1.Tocompare thepsychometrics ofdigitalandpaper-pencil
cognitive tests.Scoredistributions, test-retest reliability, and
construct validityofthefollowing testswillbecompared: Trail
MakingTest(TMT),ReyOsterrieth Complex FigureTest
(ROCFT), DigitSpanTest,Controlled OralWordAssociation Test
(COWAT), Category FluencyTest,ReyAuditory VerbalLearning
Test(RAVLT), ClockDrawingTest,StarCancellation Test,[ADDRESS_279963],MiniMentalStatusExam2(MMSE-2).
2.Toassessthedegreeofagreement between thealgorithm and
manualscoresforthedigitalReyOsterrieth Complex FigureTest
andClockDrawingTest.
3.Toestimate regression-based normsandreliablechange
indices.
4.Toestimate factorloadings forastructural equation model
describing cognition intermsofdistinctcognitive domains
Secondary objective(s) Thesecondary objective ofthestudyistoexploreusability
aspects ofIntelliSpace Cognition.
Participating partiesand Sponsor: PhilipsElectronics Nederland B.V.,
theirroles •InternalEthicsapproval
•Providing Principal Investigator
•StudyDesign
•Monitoring
•Datastorage
•Dataintegritycheck
•Dataanalysis
•Report
Studyco-ordinator:
•Selection ofroomsfordatacollection
•Selection ofpsychometrists
•IRBapproval
•Recruitment ofparticipants
•Datacollection
Subjects Thestudywillincludeatminimum N400anduptoN=[ADDRESS_279964] techniques willbeusedtorecruit
participants.
Title:ClinicalInvestigation Plan Author:LauraKiaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version:2.0 Date:2019-02-18 Status:Approved Page:8of35
IRBMANAGER PI[INVESTIGATOR_8571] —QIPROJECT
PhilipsResearchP11ILIPS
Inclusion Criteria:
•Examinee’s primarylanguage (language mostoftenspoken)
mustbeEnglish.
•Ifexaminee hasvisionimpairment orhearingloss,mustbe
corrected tonormal.
•Musthavenormalfineandgrossmotorability
•Musthaveuseoffingers,hands,andarmstobeabletousea
penciltowritesymbols.
•Mustbeabletounderstand subtestinstructions and
participate fullyintesting.
Exclusion Criteria:
•Evidence ofcurrentcognitive impairment.
•Disruptive behavior orinsufficient compliance withtestingto
ensureavalidassessment.
•Examinee mustnotbecurrently admitted toahospi[INVESTIGATOR_307],
assisted living,nursinghomeorapsychiatric facility.
•Examinee mustnotbediagnosed withaneurological disorder
ordisease(e.g.,Parkinson’s, braintumor,stroke,TBI,
epi[INVESTIGATOR_002] [if#seizures 2andnotreceiving ongoingtreatment
forseizures, andnotcurrently seekingmedicalevaluation or
attention relatedtoseizures, examinee canbeaccepted],
encephalitis, dementia, language disorder(expressive or
mixedreceptive/expressive excluded; articulation disorder is
ok),learningdisorder.
•Mustnothavebeenunconscious relatedtotraumatic brain
injuryor“medical condition” >20minutes(however, e.g.,heat
stroke,medication inducedareOk)oranyhead-injury
resulting inanovernight hospi[INVESTIGATOR_231999].
•Anyhistoryofamedicaleventrequiring resuscitation inwhich
examinee wasnon-responsive for>15minutes.
•Mustnothavecurrentorrecentfunctional change(abilityto
carryoutusualdutiesatwork,inschool,IADLs[driving,
shoppi[INVESTIGATOR_007], managing money],etc.)duetocognitive change.
•Examinee mustnotbereceiving chemotherapy treatment, or
havereceived chemotherapy treatment inthepast2months.
•Examinee mustnothaveahistoryofECTorradiation tothe
CNS.
•Examinee mustnotbe(currently orinthepast)diagnosed
withapsychotic disorder, orcurrently diagnosed withamood
disorder (however, MajorDepressive Disorder inremission or
withnocurrentepi[INVESTIGATOR_1865], andDysthymic andAdjustment
Disorders, areacceptable) orananxietydisorder with
symptoms significant enoughtointerfere withoptimaltest
performance.
•Autoimmune disorder (e.g.,LUPUS, MultipleSclerosis)
•Examineemustnotbecurrently diagnosed withsubstance
abuseordependence, orhavecarriedanysubstance abuse
ordependence diagnosis inthepastyear(>1yearin
remission diagnoses areOk).Longtermalcoholabusersare
excluded aswell(e.g.,abusedsubstance formorethan10
years).
•AnyhistoryofAutismSpectrum Disorder orIntellectual______________________________
Disability.
Title:ClinicalInvestigation Plan Author:LauraKlaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version:2.0 Date:2019-02-18 Status:Approved Page:9of35
IRBMANAGER PI[INVESTIGATOR_8571] —QIPROJECT
PhilipsResearchP1—IILIPS
•Theexaminee mustnotbecurrently takingmedication that
mightimpacttestperformance (e.g.,anti-convulsants,
antipsychotics, benzodiazepi[INVESTIGATOR_1651], psychostim ulants,opi[INVESTIGATOR_232000],
tricyclicantidepressants, somenorepi[INVESTIGATOR_232001]). Mostantihypertensive medications andstatinsare
acceptable.
•Ifpreviously diagnosed withanyphysical condition orillness
thatmightdepresstestperformance, illnessmustnotinterfere
withnormalcognitive functioning atwork,school,ADLs,etc.
Diabetes, hypothyroidism, andhypertension areacceptable if
controlled.
•Exclude primarily nonverbal oruncommunicative. Mustnot
haveadiagnosis ofaphasia.
•Examinees shouldnothavereceived neuropsychological
testingalthough previous MMSEtestingisallowed ifmore
than6monthsprior
•Examineemustnotbeseeking medicaldiagnostic procedures
forcognitive difficulties fromamedicalprofessional.__________________________
•Non-valid healthinsurance in[LOCATION_003].
Investigation design Thestudyhasarandomized, counterbalanced designwithtwo
conditions towhichparticipants willbeassigned randomly with
minimization fordemographic variables.
Investigation procedures Thestudyconsists oftwophases. Allparticipants inphase 1will
beinvitedtoparticipate intwoassessments thatwilltakeplace
withatimeintervaloftwoweeksbetween thetwotimepointsto
minimize retesteffects.Participants (totalN=400)willbe
randomly assigned tooneofthefollowing groups:
-GroupA(n=100)completes digitaltestsinphase 1and
paper-pencil testsinphase2,
-GroupB(n100)completes paper-pencil testsinphase 1
anddigitaltestsinphase2,
-GroupC(n50)completes digitaltestsinbothphases,
-GroupD(n=50)completes paper-pencil testsinboth
phases,
-GroupE(n=100) onlycompletes digitaltestsinonephase
(50%ofgroupEwillbeenrolled inphase 1andtheother
50%ofgroupEwillbeenrolled inphase2).
Ifthetimeline allowsforit,upto50additional participants aged
50-54willbeincluded ingroupEtostretchtheagerangeforthe
regression-based norms,makingthegroupsizeupton150and
thetotalsamplesizeuptoN=450.
ThedataofgroupAandBareusedtocompare score
distributions within-subjects.
ThedatafromgroupsA-D(phase 1)areusedtocompare score
distributions between-subjects (aim1).
Title:ClinicalInvestigation Plan Author:LauraKlaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version: 2.0 Date:2019-02-18 Status:Approved Page:10of35
IRBMANAGER PI[INVESTIGATOR_8571] —QIPROJECT
PhilipsResearchPHILIPS
ThedataofgroupCandDareusedtoassessandcompare test-
retestreliability (aim1)andassessreliablechangeindices(aim
3).
ThedataofgroupA(phase1),groupC(phase1)andgroupE
areusedtoestimate regression basednormsforthedigitaltests
(aim3),aswellastoestimate factorloadings forthestructural
equation model(aim4).
ThedataofgroupA(phase1),groupB(phase1),groupC(phase
1)andgroupD(phase1)areusedtocompare construct validity
(aim1).
Participants willberandomized withminimization fordemographic
variables (gender, age,education level,ethnicity).
Assuming adropoutrateof20%wewilloversample ourdesired N
by[CONTACT_232022], resulting insampling of480participants.
Thecompleted testswillbescoresby[CONTACT_232023]-trained raters,with
doublescoringof30%ofparticipants toassessinter-rater
agreement.
Scoringalgorithms fortheROCFTandtheClockDrawingTestare
appliedpost-data collection. Thescoresestimated by[CONTACT_232024]-trained raters(n=6;aim2).Thedatacollected duringthis
studyareonlyusedforvalidation andnotusedinanywaytotrain
thesescoringalgorithms.
Eachassessment willlastapproximately 1.5hours.
At-Home Subject
Procedures
Devices
Checkeachboxasappropriate
andaddabriefdescription of
thedevice(s)—e.g., fitness
tracker, VRgoggles,breast
pump,electrictoothbrush,
ELAN,MRIscanner.NOTAPPLICABLE
None
Mock-up (seeICBEFAQdefinition):
Survey/questionnaire (ifcopyrighted, ensurepermission for
use):
Usability questionnaire
Interview/focus groupwithaudio/video tapi[INVESTIGATOR_007]**:
Interview/focus groupwithoutaudio/video tapi[INVESTIGATOR_007]**:
**seedecision flowchart regarding interviews vsQIvsconsulting
https://share-intra.philips.com/sites/STS2O 131115093003/ICBE-
FAO/Lists/Photos/interviews%20criteria%20flowchart%2Ofeb2Ol 8.
Deviceswillbedescribed fully
inSection2.1ofthestudy
protocol.FDAorCE-approved medical
devicewithinintended use:
JFDAorCE-approved medical
deviceoutsideintended use:
FDAorCE-approved non-
medicaldevicewithinintended
Thedigitaltestswillbeprovidedtotheuse:A
Title:ClinicalInvestigation Plan Author:LauraKlaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version:2.0 Date:2019-02-18 Status:Approved Page:11of35
IRBMANAGER PI[INVESTIGATOR_8571] —QIPROJECT
PhilipsResearchP1—IILIPS
participants onanIpadPro(Apple). Ithasascreensizeof12.9-inch witha
screenresolution of2732x2048. Participants willusetheApplepencilforthe
IpadProtoperformthetests(seeFigure).BoththeiPadProaswellasthe
ApplePencilarewipedcleanafteruseby[CONTACT_232025].
Todigitallyadminister thedigitalteststotheparticipants, thetestleaderwill
startthetestviathesoftware prototype onaregularlaptopthatwillbe
provided by[CONTACT_191731](seeFigure).
TheIpadpro,Applepencilandtheregularlaptopwillallbecommercially
available devicesandusedwithintheirintended use.
FDAorCE-approved non-medical device outside intended
use:
Invitromedicaldevice:
Medicaldeviceprototype***:
Non-medical deviceprototype***:
Software prototype***, non-medical:
Aselection ofthedigitaltestsareadministered totheparticipants viaa
software prototype designed by[CONTACT_191731](Production Equivalent Device).
Software prototype***, medical:
Aselection ofthedigitaltestsisadministered totheparticipants viaamedical
software prototype (onaniPad)designed by[CONTACT_191731](IntelliSpace Cognition).
LIOther:
***Before astudyemploying prototypes maystart,aDeclaration of
Conformity (D0C)needstobeissuedby[CONTACT_232026].WiththisDoC,Philipsdeclares thatthe
devicecansafelybeusedinthestudy.Itmaybeneededto
workaccording tosomeformalstandards tobuildupthis
evidence (e.g.withrespecttobio-compatibility orsterility).
DoCneeded(briefoverview oftheactionsthatwillbetaken
togettheDeclaration ofConformity. SeePhilipsResearch QMS
procedure “Procedure ProductRelease (QR-PRO-36”. Give
detailsofhowtheprojectwilldealwiththeregulatory___________________________
requirements. ConsulttheQ&Rofficewhenneeded):
Milestones ICBEreviewwillbecompleted 17December 2018
IRBreview willbecompleted 15Feb2019
Datacollection willstartin15March2019
Datacollection fortimepoint1willbecompleted 15June2019
(withfourexaminers)
Datacollection fortimepoint2willbecompleted 15Sept2019
(withfourexaminers)
Dataanalysis willbecompleted 15October2019__________________________
Reportwillbecompleted 15October2019
Claims Willyouobtainregulatory (FDA,CE)approval foranewproductor
service, anewindication, oranewmarketing claim?________________________
LiYes NoN/A510Kexempt
Title:ClinicalInvestigation Plan Author:LauraKlaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version:2.0 Date:2019-02-18 Status:Approved Page:12of35
IRBMANAGER PI[INVESTIGATOR_8571] —QIPROJECT
PhilipsResearchP1—IILIPS
IfYES, inwhatcountries willtheclaims beregistered?
ElNetherlands [LOCATION_003] El[LOCATION_013] ElChina
ElIndia ElBelgium El[LOCATION_006] ElKenya
ElOther:
Haveyoudeveloped alistofclaimsthatyouwouldliketoassert
foryourproductorservice? YesElNo
.ElNotRequired (notalocal/state/country requirement)External Research EthicsRequired (applyforitAFTERICBEapproval)Committee (REC)ApprovalElApproval alreadyobtained (uploadforreviewby[CONTACT_232027])
Note:ifyourdocument isnotinElRECReview iswaived (upload review waiver)
EnglishorDutch,includeanEnglishElREChaswaived requirement forinformed consent (upload
transiation waiver)
ElCheckthisboxifmorethanoneRECisinvolved inthisstudy
and_identify_them:
Submission toCompetent Notapplicable (510Kexempt)
Authorities
Checktheapplicable optionconcerning Competent Authority
approval formedicaldevicestudies:
ElNosubmission toCompetent Authority needed,sincenonon-
released medicaldeviceinvolved
ElApproval fromCompetent Authority ismandatory forthisstudy
withanon-released medicaldevice
Note:Released medicaldevicemeansadevicethatise.g.CE-
marked(93/42/EEC) ifstudytakesplaceinEU,orhas510kif
studytakesplacein[LOCATION_003].
Ourdevicewillbemarketed asaClass-IlMedicalDeviceinthe
US.Thedeviceis510(k)exemptby[CONTACT_232028].
Link:https://www.accessdata.fda.gov/scripts/cdrh!cfdocs/cfPCD/cla
ssification.cfm?id3768
Database registration ElNone
ClinicalTrials.gov
ElOther:
TypeofLegalAgreement ElNonerequired ElMRAExhibit
forthisstudy Contract Purchase Order
WewillworkwithaCR0(supplier) viaapurchase orderand
additional CR0agreement
StatusofLegalAgreement ElNAElNotstarted InProcess ElInPlace
NameofLegalRep:JenniferNene
lPStrategySeeCR0agreement
ICBETraining isrequired . .. *YES,thistraining iscompleted asrequired by[CONTACT_232029],thistrainingisnotcompleted asrequired by[CONTACT_232027]*:
Title:ClinicalInvestigation Plan Author:LauraKiaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version: 2.0 Date:2019-02-18 Status:Approved Page:13of35
IRBMANAGER PI[INVESTIGATOR_8571] —QIPROJECT
PhilipsResearchP1—IILIPS
2INVESTIGATIONAL DEVICE
2.1DeviceSummary
Thischaptercontains asummary description oftheinvestigational deviceanditsintended purpose.
Summary device PhilipsIntelliSpace Cognition (ISC)isadigitalproposition fromtheDigital
description Cognitive Diagnostics (DCDx) venture. Itisadigitalaidwhichsupports
HealthCare Professionals (HCP5) inassessing thecognition ofindividuals
withinahealthcare facility. Itconsists oftwointerfaces connected totheDCDx
module inthecloud.ISCwillbehostedontheHealthSuiteDigitalPlatform
(HSDP). Thefirstinterface isthepatient’s interface andispresented viaatablet
tocollectdataonhowthepatientperforms aseriesoftests.Thesecond
interface istheclinician’s interface andistypi[INVESTIGATOR_232002]. Itallows
fortestsortestbatteries tobeselected, observations noted,dataanalytics
performed andthegeneration ofareport.PhilipsISCisaClass-Il Medical
DeviceintheUSandprovides objective dataregarding cognition viascoring
algorithms thatHCPscanusetoinformdiagnostic decision makingand
treatment planning. Itenables tracking cognition overtimeandoffersthe
possibility ofnewoutcome measures. ISCcanbeusedinavarietyofhealthcare
environments suchasneurology andneuropsychology practices.
Inthisstudy4devices/tools willbeused:
•AversionoftheISCmedicalproduct(asengineered inaccordance
withtheHealthWorks QMS)andthatisverifiedtobeusedfordata
collection andprovides theinterface ofthefinalproductforthetests:
TMT,ClockDrawingTest,MMSE-2, ROCFT, andDigitSpanTest.
•Aproduction equivalent (research platform) thatprovides:[ADDRESS_279965],RAVLT,COWAT andStar
Cancellation.
•Papertests:TrailMakingTest,ReyOsterrieth Complex FigureTest,
DigitSpanTest,Controlled OralWordAssociation Test,Category
FluencyTest,ReyAuditory VerbalLearning Test,ClockDrawingTest,
StarCancellation Test,0Cancellation Test,MMSE-2. Inadditiona
namingtestinpaperformatwillalsobeincluded.
•AMoCApaperbasedscreener test.
Inthisstudy,thesedevices/tools willbeusedtoinvestigate scoredistributions,
construct validityandtest-retest reliability.
Summary ThelntelliSpace Cognition toolisintended tobeusedasanadjunctive toolin
intended purpose theassessment ofanadults’levelofcognitive functioning.
TheIntelliSpace Cognition toolprovides healthcareprofessionals withan
overview ofboththeoverallcognitive performance aswellasspecific
cognitive domains.
TheIntelliSpace Cognition toolprovides healthcareprofessionals witha
methodtocompare aperson’s cognitive performance overdifferent
assessments (moments intime).
Title:ClinicalInvestigation Plan Author:LauraKiaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version:2.0 Date:2019-02-18 Status:Approved Page:14of35
IRBMANAGER PI[INVESTIGATOR_8571] —QIPROJECT
PhilipsResearchPHILIPS
TheresultsfromIntelliSpace Cognition toolareintended tobeusedby
[CONTACT_232030].
Thedatacollected by[CONTACT_232031].
ThelntelliSpace Cognition toolisnotintended asastand-alone oradjunctive
diagnostic device.
Theassessments provided viatheIntelliSpace Cognition toolmaybeusedfor
awidevarietyofpatientgroups,aswellashealthyindividuals whenaHCP
wishestogainmoreinsightintocognitive performance.
Thecognitive modelofIntelliSpace Cognition toolhasbeen
scientifically validated forassessing thecognition ofhealthypeoplein
theagegroupof55-80.
TheIntelliSpace Cognition toolhasnotbeenvalidated forusewith
adultsundertheageof55orovertheageof80anddoesn’tinclude
normative dataforadultsundertheageof50orovertheageof80.
Maintenance ofthedevicewillbecarriedoutby[CONTACT_232032]. Cleaning
ofthedevicewillbecarriedoutasneededby[CONTACT_232033]. Whenthe
deviceisnotusedfortheclinicalinvestigation itisplacedinsidealocked
cabinet inalockedofficeatthesites.Atclinicalinvestigation termination orDisclaimer:
.
Population Thetestsprovided viatheIntelliSpace Cognition maybeusedforanyone
description whereanoverview ofcognitive functioning isrequired provided theyarepart
ofthedemographic groupasdescribed inthesectiontitled“subjects”.
Manufacturer Thelegalmanufacturer isPhilipsHealthWorks forwhichFDA21CFR820.[ADDRESS_279966](asengineered inaccordance withthe
modelltype HealthWorks QMS)andthatisverifiedtobeusedfordatacollection and
provides theinterface ofthefinalproductforthetests:TMT,ClockDrawing
Test,MMSE-2, ROCFTandDigitSpanTest.
Aproduction equivalent (research platform) thatprovides:0Cancellation
Test,Category FluencyTest,RAVLT, COWAT andtheStarCancellation.
Software version Software version1.0.0oftheISCproduct willbereleased fortheclinical
investigation.
Software version3.10.6A oftheproductequivalent willbeusedfortheclinical
investigation.
Accessories iPadProtablets(Apple)
Applepencils
Regularlaptops
Traceability
procedure
Title:ClinicalInvestigation Plan Author:LauraKiaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version:2.0 Date:2019-02-18 Status:Approved Page:15of35
IRBMANAGER PI[INVESTIGATOR_8571]—Ql PROJECT
PhilipsResearchP11ILIPS
closure,thedevicewillbereturned toPhilipsandchecked by[CONTACT_232034].The
devices, SWandaccessories areuniquely identified andlistedinappendix B
Validation ISC —devicelist.
Required training Persons qualified toadminister theneuropsychological tests,i.e.a
psychologist orpsychometrist, willusetheinvestigational devicestocollect
dataaspartoftheclinicalinvestigation. Employees ofPhilipswilltrainthe
researchers foroperation oftheinvestigational devices.
Specific N/A
procedure acts
DeviceLabeling Thesoftware willcontainalabelwiththetext;notforclinicaluse.
2.2Intended purpose
TheIntelliSpace Cognition toolisintended tobeusedasanadjunctive toolintheassessment ofan
adults’levelofcognitive functioning.
TheIntelliSpace Cognition toolprovides healthcareprofessionals withanoverview ofboththeoverall
cognitive performance aswellasspecificcognitive domains
TheIntelliSpace Cognition toolprovides healthcareprofessionals withamethodtocompare a
person’s cognitive performance overdifferentassessments (moments intime).
TheresultsfromIntelliSpace Cognition toolareintended tobeusedby[CONTACT_232035].
Thedatacollected by[CONTACT_232036]-alone oradjunctive diagnostic device.
Theassessments provided viatheIntelliSpace Cognition toolmaybeusedforawidevarietyofpatient
groups,aswellashealthyindividuals whenaHCPwishestogainmoreinsightintocognitive
performance.
Disclaimer:
•Thecognitive modelofIntelliSpace Cognition toolhasbeenscientifically validated for
assessing thecognition ofhealthypeopleintheagegroupof55-80
•TheIntelliSpace Cognition toolhasnotbeenvalidated forusewithadultsundertheageof55
orovertheageof80anddoesn’tincludenormative dataforadultsundertheageof50orover
theageof80.
2.3DeviceDescription
PhilipsIntelliSpace Cognition (ISC)isadigitalproposition fromtheDigitalCognitive Diagnostics
(DCDx)venture. Itisadigitalaidwhichsupports HealthCare Professionals (HCPs) inassessing the
cognition ofindividuals withinahealthcare facility. Itconsists oftwointerfaces connected totheDCDx
module inthecloud.ISCwillbehostedontheHealthSuiteDigitalPlatform (HSDP). Thefirstinterface
isthepatient’s interface andispresented viaatablettocollectdataonhowthepatientperforms a
seriesoftests.Thesecondinterface istheclinician’s interface andistypi[INVESTIGATOR_232002].It
Title:ClinicalInvestigation Plan Author:LauraKlaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version:2.0 Date:2019-02-18 Status:Approved Page:16of35
IRBMANAGER PI[INVESTIGATOR_8571] —QIPROJECT
PhilipsResearchP1—IILIPS
allowsfortestsortestbatteries tobeselected, observations noted,dataanalytics performed andthe
generation ofareport.PhilipsISCisaClass-IlMedicalDeviceintheUSandprovides objective data
regarding cognition viascoringalgorithms thatHOPscanusetoinformdiagnostic decision making
andtreatment planning. Itenablestrackingcognition overtimeandoffersthepossibility ofnew
outcome measures. ISCcanbeusedinavarietyofhealthcare environments suchasneurology and
neuropsychology practices.
Inthisstudy4devices/tools willbeused:
•AversionoftheISCmedicalproduct(asengineered inaccordance withtheHealthWorks
QMS)andthatisverifiedtobeusedfordatacollection andprovides theinterface ofthefinal
productforthetests:TMT,ClockDrawingTest,MMSE-2, ROCFT, andDigitSpanTest.
•Aproduction equivalent (research platform) thatprovides:0Cancellation Test,Category
FluencyTest,RAVLT,COWAT andStarCancellation.
•Papertests:TrailMakingTest,ReyOsterrieth Complex FigureTest,DigitSpanTest,
Controlled OralWordAssociation Test,Category FluencyTest,ReyAuditory VerbalLearning
Test,ClockDrawingTest,StarCancellation Test,0Cancellation Test,MMSE-2. Inadditiona
namingtestinpaperformatwillalsobeincluded.
•AMoCApaperbasedscreener test.
Inthisstudy,thesedevices/tools willbeusedtoinvestigate scoredistributions, construct validityand
test-retest reliability.
TheISCproduction equivalent thatwillbeusedforadministering 0Cancellation Test,Category Fluency
Test,RAVLT, COWAT andStarCancellation hastheexactsamepatientinterface astheend-product.
Thedigitaltestswillbeprovided totheparticipants onaniPadProtablet(Apple). Ithasascreensize
of12.9-inches withascreenresolution of2732x2048. Thisistheexactsametabletasrequired foruse
ofthefinalISCproduct.
Participants willusetheApplepencilfortheiPadProtablettoperformthedigitaltests(seeFigure1).
Thetabletwillpresentinstructions foreachtesttoparticipants viabothwrittentextandaudio
recordings. Aresearcher willobserve inordertoensurethattheparticipant understands andfollows
theinstructions (seeFigure2).TheiPadProtablet,Applepencilandtheregularlaptop,whichmaybe
usedby[CONTACT_232037],areallCEmarkeddevices.
Figure1.PadproandApplepencilusedby[CONTACT_232038]2.Regularlaptopusedby[CONTACT_232039](verified fordatacollection, SWversion1.0.0)areonly
utilizedtocollectdata.Thescoringalgorithms fortheROCFTandtheClockDrawingTesthaveeither
notyetbeenimplemented ortheoutputofthosethathavebeenimplemented willnotbeconsidered
relevant. Thedatacollected withthedeviceduringtheclinicalinvestigation willbeusedtoassessthe
equivalence ofoutputsfromautomatic scoringby[CONTACT_232040]. Only
whentheoutputofthealgorithms havehighagreement withmanualscoresoftherespective test,the
algorithms willbeintegrated intothefinalISCproduct.
3JUSTIFICATION
WhiletheISCproductmaybeusedinavarietyofsituations themostlikelyiswithinaneurology office.
Theuse-case forISCisthattherawdataarecollected viatheipadunderthesupervision ofanassistant.
Title:ClinicalInvestigation Plan Author:LauraKlaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version: 2.0 Date:2019-02-18 Status:Approved Page:17of35
IRBMANAGER PI[INVESTIGATOR_8571]—QI PROJECT
PhilipsResearchP1—IILIPS
Subsequently, variousalgorithms areappliedtoscoretheindividual tests.Thesescoresarethenfed
intoacognitive model,resulting ineasy-to-interpret cognitive domainscores.Thedomainscoresare
normreferenced by[CONTACT_654],andoptionally by[CONTACT_547],education, andethnicity. TheoutputofISCisused
by[CONTACT_232041]/herarriveathis/herdiagnosis orforcreatinganoptimaltherapyplan.In
thecaseofrecurring visitsthecognitive domainscoresgivetheneurologist (orHOP)metrics to
objectively assesschangeovertime.
A[LOCATION_003]neurologist willonaveragesend13%ofhispatientsforafullneuropsychological assessment
whileinanidealworldhe/shewouldliketosend36%(TheMarkeTech Group,2018).Acommon reason
fornotreferring forafullassessment isthewaitingtimeof3-6months(TheMarkeTech Group,2018).
Thereisaclearunmetneedforasolutionthatgivesmoreinformation thanasimplescreener toolbut
withinanactionable time-window, preferably duringthepatientvist.Forthemajority ofpatients, ISO
doesn’treplacethefullneuropsychological assessment butinsteadhelpstriagepatientssothatpeople
thatneedafullassessment canbequicklyidentified andfasttracked.
Incurrentclinicalpractice, neurologists perform anMMSEorMoCAscreener andoccasionally a
haphazard cognitive testsuchasaclockdrawingorasimplewordrecalltrial.Ingeneraltheneurologist
doesnotpossess theskill(ortime)toscoretestsandnormative dataarerarelyused.Computerized
cognitive assessment canalleviateissueswithhaphazard cognitive testingandallowmoreaccurate
cognitive assessments tobeperformed attheneurology office.Digitized cognitive testshaveanumber
ofimportant benefitscompared topaper-pencil testsincluding normscoresatthelevelofcognitive
domains, continuous normscoresoverage,morestandardized administration andscoring,dynamic
presentation ofthetestcontentaccording totheabilitiesofthepatient,moresensitive measurement of
reactiontime,additional andpotentially moresensitive outcome measures, andthepossibility toreplay
testperformance (Baueretal.,2012;Klaming &Vlaskamp, 2017;Miller&Barr,2017;Schatz &
Browndyke, 2002).
TheheartofIntelliSpace Cognition isthecognitive model.Themodelisbasedonstructural equation
modelling, hasitsrootsinpublished literature andknowledge gleaned fromkeyopi[INVESTIGATOR_232003]. Thisprovided mappi[INVESTIGATOR_232004].
Thesemappi[INVESTIGATOR_232005]148healthyindividuals inanearlystagepi[INVESTIGATOR_232006],
andshowed excellent fit.Moreover, thecognitive domains specified by[CONTACT_232042]51strokepatientsand48TBIpatients. Themodeliscurrently basedon
accepted testmeasures. Inthefutureitmaybepossible toincorporate new(tobevalidated) outcome
measures intothemodelandsomakeitmoresensitive orreducethenumber oftestsneeded. For
example incurrentneuropsychological clinicalpractice, interpretation ofTMTperformance ismostly
restricted tototalcompletion timeanderrors.Otherbehaviours duringTMTperformance arelikelyto
revealadditional information, primarily aboutexecutive functioning, butinthecurrentpaper-pencil based
formatofthetestitisdifficultorimpossible tomeasure thesebehaviours. Research hasalreadystarted
tolookintonewoutcome measures fortheTMTthatarepossible withdigitalmeasurement suchas
inter-element variability andaseparation oflayout-related processes fromexecutive processes onTMT
B(Klaming &Vlaskamp, 2017).Inaddition, digitalassessment enablesmoreaccurate measurement of
totalcompletion timeandamorestandardized assessment oferrorsduringperformance ofthetest.
Anotherexample ofadigitaltestisthedigitaladministration oftheROCFTwhichprovides anumberof
important benefits overpaper-pencil administration. Probably mostimportantly, digitaladministration
enablesautomatic scoringofthedrawing whichnotonlysavestimeinthescoringofthetest,but
moreover contributes tobetterstandardization ofscoring. Additionally, itwillbepossible toimplement
different scoringalgorithms including bothquantitative andqualitative scoringalgorithms. Incurrent
neuropsychological clinicalpractice, formalized qualitative scoring isonlyrarelyperformed despi[INVESTIGATOR_232007]’s cognitive functioning
beyondtheinformation provided by[CONTACT_232043](Akshoomoff &Stiles,1995;Anderson,
Anderson, &Garth,2001;Bennett-Levy, 1984;Chiulli,Haaland, Larue,&Garry,1995;Deckersbach et
al.,2000;Hamby,Wilkins, &Barry,1993;Shorr,Delis,&Massman, 1992).Besidesautomatic scoring
whichwouldsavetimeanddecrease variability inscoringforbothqualitative andquantitative scoring
systems, digitaladministration allowsfortheextraction ofadditional datasuchastouch/pencil pressure
andspeedwhichmayprovideadditional information aboutthepatient’s cognitive functioning. Theuse
Title:ClinicalInvestigation Plan Author:LauraKlaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version:2.0 Date:2019-02-18 Status:Approved Page:18of35
IRBMANAGER PI[INVESTIGATOR_8571] —QIPROJECT
PhilipsResearchPHILIPS
ofcomputerized neuropsychological assessment hasbeenrecommended (Baueretal.,2012;Miller&
Barr,2017;Strauss,Sherman, &Spreen, 2006).
ThelSCcognitive modelisbasedonmappi[INVESTIGATOR_232008]-pencil testswhichhavemanyyearsofvalidation. Itisvitalforthe
validityofthedigitaltests,thecognitive modelandtheirsubsequent useinclinicalpracticethatthe
comparibility between thedigitaltestsontheISCplatformandthecorresponding paper-pencil testsis
shown.Thisstudyaimsatinvestigating thecomparibility oftherelevant digitalandpaper-pencil
cognitive tests,establishing thepsychometric properties ofthedigitalcognitive testsandcollecting
normative dataforthedigitaltestssothatthedigitaltestsandthecognitive modelcanbeusedin
clinicalpractice.Normative dataisdatafromareference population thatestablishes abaseline
distribution forascoreormeasurement, andagainstwhichotherscoresormeasurements canbe
compared. Forthisobjective, datasubjectsareinformed onthedatawecollectandthepossiblere
useofthisdata,including by3rdparties.
4RISKSANDBENEFITS ASSESSMENT
Ihavecreatedanduploaded ariskmanagement summary matrix
Ihavecreatedanduploaded ariskmanagement plan
Asummary overview oftherisksandbenefits oftheinvestigational deviceandtheclinicalprocedure
aDDlied inthisclinicalinvestioation arelistedinthetablebelow.
Anticipated clinical IntelliSpace Cognition isadigitaltooltoassesscognition inanefficient
benefits way.Itreplaces thepaperworkflow by[CONTACT_232044].
Anticipated adverse Therearenorisksofanyadverseevent,mildorserious
deviceeffects
Residual risks -Noriskforparticipants
associated with
investigational device -Dataloss(riskforvalidity)
[asidentified inrisk
analysis report]
Risksassociated with -Privacybreachwhendevicesarestolenandthesystemisnotbeing
participation inclinical loggedoff
investigation
-Fatigueduringparticipation (riskisalmostzero)
Possible interactions Therearenointeractions withconcomitant medicaltreatments
withconcomitant
medicaltreatments
Stepsthatwillbetaken -Privacybreachwhendevicesarestolenandthesystemisnotbeing
tocontrolormitigate loggedoff—systems willbeloggedoffandstoredinalockedcabinet
risks
Title:ClinicalInvestigation Plan Author:LauraKlaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version:2.0 Date:2019-02-18 Status:Approved Page:19of35
IRBMANAGER PI[INVESTIGATOR_8571] —QIPROJECT
PhilipsResearchP1—IILIPS
-Fatigueduringparticipation -protocolwillincludeashortbreakto
preventfatigue
Risk-to-benefitTherearenosubstantialrisksorpotentialriskspossibleinthistrialfor
rationaleparticipantsandtherearenoriskofanyadverseevent,mildorserious.
ThebenefitswillbetobeabletolaunchIntelliSpaceCognitionandin
short;speedupthecognitiveaccessprocessinclinicswithuseof
Artificiallnteligence,by[CONTACT_232045]/subjectstowhichonesneedsa
morerobustcognitiveassessmentwithaneuropsychologist.
Thebenefitsoftheuseoftheinvestigationaldeviceoutweightherisks.
SOBJECTIVESANDHYPOTHESES
Thischapterdescribestheobjectivesandhypothesesoftheclinicalinvestigation,aswellasthe
claimsandintendedperformanceoftheinvestigationaldevicetobeverified,andtherisksand
anticipatedadversedeviceeffectstobeassessed.
Primaryobjective:
Thestudyhasfouraims.
1.Tocomparethepsychometricsofdigitalandpaper-pencilcognitivetests.Scoredistributions,test-
retestreliability,andconstructvalidityofthefollowingtestswillbecompared:TrailMakingTest(TMT),
ReyOsterriethComplexFigureTest(ROCFT),DigitSpanTest,ControlledOralWordAssociationTest
(COWAT),CategoryFluencyTest,ReyAuditoryVerbalLearningTest(RAVLT),ClockDrawingTest,
StarCancellationTest,0CancellationTest,MiniMentalStatusExam2(MMSE-2).
2.ToassessthedegreeofagreementbetweenthealgorithmandmanualscoresforthedigitalRey
OsterriethComplexFigureTestandClockDrawingTest.
3.Toestimateregression-basednormsandreliablechangeindices.
4.Toestimatefactorloadingsforastructuralequationmodeldescribingcognitionintermsofdistinct
cognitivedomains.
Secondaryobjective(s)
ThesecondaryobjectiveofthestudyistoexploreusabilityaspectsofIntelliSpaceCognition.
Primaryhypotheses
Thefollowingprimaryhypotheseswillbetestedinthestudy:
Aim1.
A.Digitalandpaper-pencilnormedtestscoresarecomparable.Weconsiderthetwoversionsofa
testcomparablewhenthedigitalnormedscoreisonaveragewithin.3sdofthepapernormed
scoreandthetwonormedscorescorrelateatleast.6.
B.Test-retestreliabilityofthedigitaltestsiscomparabletotest-retestreliabilityofthepaper-pencil
tests.Weconsiderthereliabilitytobecomparablewhenweobservenosignificantdifferenceina
z-testbetweenthedigitalandthepaper-penciltest-retestcorrelations.
Title:ClinicalInvestigationPlanAuthor:LauraKlamingCompanyRestricted
DodD:ICBE-2-28674Version:2.0Date:2019-02-18Status:ApprovedPage:20of35
IRBMANAGERPI[INVESTIGATOR_8571] —QIPROJECT
PhilipsResearchP1—IILIPS
C.Construct validityofthedigitaltestsiscomparable totheconstruct validityofthepaper-pencil
tests.Weconsider construct validitytobecomparable whenconfirmatory factoranalysisyieldsthe
samefactorstructure fordigitalandpaper-pencil tests.
Aim2.
D.Thescore(s) provided by[CONTACT_232046](>.8)tothescoreprovided by[CONTACT_232047].
Aims3&4havenoaccompanying hypotheses.
Secondary hypotheses
Thefollowing secondary hypothesis willbetestedinthestudy:
1.Theusability oftheISCdeviceissufficient forparticipants orpsychologists/psychometrists.
Thiswillbeexplored withaquestionnaire forparticipants aswellasaregistration by[CONTACT_232048]/psychometrist ofhowmanyparticipants wereunabletocomplete atestandwhy.
Claimsandintended performance
Thestudyaimstoprovideinformation thatcanbeusedtosubstantiate theclaimslistedinthetable
belowfromtheregulatory planofISC,alongwiththestudyaimcovering theclaim.
ClaimDescription Covered by
[CONTACT_232049] 4
cognitive domains
Automated scoringalgorithms thatgivereproducible scorestimeaftertime 2
Digitaltestshavesimilarpsychometrics topapertestmeasures 1
Longitudinal reporting ofperformance atthelevelofcognitive domains 3&4
Usability by[CONTACT_202473] —high“easytouse”scoreforelderlyusers Secondary objective
Usability by[CONTACT_202473] -highusersatisfaction whenusingdigitalplatform SecondaryobJectiveA
Risksandadversedeviceeffects:
Thefollowing risksandanticipated adversedeviceeffectstobeassessed:
•Privacybreach
•Participant fatigue
•Dataloss
6CLINICAL INVESTIGATION DESIGN
6.1General
Thestudyhasarandomized, counterbalanced designandconsists oftwophases(seefigure1).We
sampleparticipants according tothesampling planoutlinedbelow,toensurerepresentativeness of
thesample.Wewilloversample by20%toaccountfordropoutorincomplete data(then’sbelow
represent thedesiredcellcounts,afterdropout).
Figure1.Schematic overview ofstudydesign.
Title:ClinicalInvestigation Plan Author:LauraKlaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version:2.0 Date:2019-02-18 Status:Approved Page:21of35
IRBMANAGER PI[INVESTIGATOR_8571]—01PROJECT
PhilipsResearchP11ILIPS
Group A B C D E
100 100 50 [ZIP_CODE]-150
DigitalPaper- DigitalPaper- Digital
pencil pencil
Paper- Digital DigitalPaper-
pencil pencil
Allparticipants ofGroupA-Dinphase 1willbeinvitedtoparticipate intwoassessments thatwilltake
placewithatimeintervaloffour-fiveweeksbetween thetwophasestominimize retesteffects.
Participants willberandomly assigned withminimization fordemographic variables (tomakesurethat
thegroupsdonotdifferintermsofgender,age,education level,andethnicity) tooneofthefollowing
groups:
-GroupA(n=100)completes digitaltestsinphase 1andpaper-pencil testsinphase2,
-GroupB(n—lOG)completes paper-pencil testsinphase 1anddigitaltestsinphase2,
-GroupC(n=50)completes digitaltestsinbothphases,
-GroupD(n50)completes paper-pencil testsinbothphases,
-GroupE(n=100-150) onlycompletes digitaltestsinonephase(50%ofgroupEwillbe
enrolled inphase 1andtheother50%ofgroupEwillbeenrolled inphase2).
ThedataofgroupAandBareusedtocompare scoredistributions within-subjects
ThedatafromgroupsA-D(phase1)areusedtocompare scoredistributions between-subjects (aim
1).
ThedataofgroupCandDareusedtoassessandcompare test-retest reliability (aim1)andassess
reliablechangeindices(aim3).
ThedataofgroupA(phase1),groupC(phase1)andgroupEareusedtoestimate regression based
normsforthedigitaltests(aim3),aswellastoestimate factorloadings forthestructural equation
model(aim4).
ThedataofgroupA(phase1),groupB(phase1),groupC(phase1)andgroupD(phase1)areused
tocompare construct validity(aim1).
Participants willberandomized withminimization fordemographic variables (gender, age,education
level,ethnicity).
Thepurpose ofaddingthe100-150participants inGroupEistoincrease thesamplesizeof
participants whocompleted thedigitaltestsforthefirsttimeforthenormdatato250-300.
Wewillusethe100setsofdigitalROCFTandClockDrawingTestdrawings, randomly drawnfromthe
fullsample, toestablish agreement between scoringalgorithms andmanualscoringby[CONTACT_10070]-trained
raters(aim2).
Title:ClinicalInvestigation Plan Author:LauraKlaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version:2.0 Date:2019-02-18 Status:Approved Page:22of35
IRBMANAGER PI[INVESTIGATOR_8571] —QIPROJECT
PhilipsResearchPP—IILIPS
6.2Investigational device(s) andcomparator(s)
Theinvestigational devicesaretheISCproductandtheISOproductequivalent. Thecomparators are
thepaper-pencil testsincluded inthestudy.
ManualscoresofthedigitalROCFTandClockDrawingTestswillbecompared tothealgorithm
scores.Scoringalgorithms fortheROCFTandtheClockDrawingTestareappliedpost-data
collection. Thescoresestimated by[CONTACT_232050]-trained raters(n=6;aim2).Thealgorithms havebeendeveloped by[CONTACT_232051]. By
[CONTACT_232052],wecaninvestigate theagreement between thetwofor
thetestsontheplatform. Thiswillbedoneby[CONTACT_232053]-rater agreement (also
knownasinter-rater reliability) between thealgorithm andexpertraters.Relativeinter-rater agreement
impliesthatthealgorithm ranksexaminees thesameasexpertraters(n=6).
6.3Subjects
Wehavespecified aSampling planthatensuresrepresentativeness fortheUSpopulation inAppendix
A.Thesampling planestablishes initialnormative reference ranges,provides psychometric evaluation
ofretestreliability, andprovides adirectvalidation ofdigitalscoresrelativetopaper-and-pencil scores.
Furthermore, thisprotocolestablishes thatolderadultscomingfromavarietyofbackgrounds
consistent withthegeneralpopulation oftheUnitedStatescanadequately followthetest
administration ruleswithminimalproctoring, understand howtointeractwiththeiPadtosuccessfully
enterhis/herresponse toitems,andasufficient behavioral samplecanbecollected toestablish
reference ranges.
Inclusion criteriaforsubjectselection
•Examinee’s primarylanguage (language mostoftenspoken)mustbeEnglish.
•Ifexaminee hasvisionimpairment orhearingloss,mustbecorrected tonormal.
•Musthavenormalfineandgrossmotorability
•Musthaveuseoffingers,hands,andarmstobeabletouseapenciltowritesymbols.
Mustbeabletounderstand subtestinstructions andparticipate fullyintesting
Exclusion criteriaforsubjectselection
•Evidence ofcurrentcognitive impairment
•Disruptive behavior orinsufficient compliance withtestingtoensureavalidassessment.
•Examinee mustnotbecurrently admitted toahospi[INVESTIGATOR_307],assisted living,nursinghomeora
psychiatric facility.
•Examinee mustnotbediagnosed withaneurological disorder ordisease(e.g.,Parkinson’s, brain
tumor,stroke,TBI,epi[INVESTIGATOR_002] [if#seizures 2andnotreceiving ongoingtreatment forseizures,
andnotcurrently seekingmedicalevaluation orattention relatedtoseizures, examinee canbe
accepted], encephalitis, dementia, language disorder(expressive ormixedreceptive/expressive
excluded; articulation disorder isok),learningdisorder
•Mustnothavebeenunconscious relatedtotraumatic braininjuryor“medical condition” >20
minutes(however, e.g.,heatstroke,medication inducedareOk)oranyhead-injury resulting inan
overnight hospi[INVESTIGATOR_231999]
•Anyhistoryofamedicaleventrequiring resuscitation inwhichexaminee wasnon-responsive for>
15minutes.
•Mustnothavecurrentorrecentfunctional change(abilitytocarryoutusualdutiesatwork,in
school,IADLs[driving,shoppi[INVESTIGATOR_007], managing money],etc.)duetocognitive change.
•Examineemustnotbereceiving chemotherapy treatment, orhavereceived chemotherapy
treatment inthepast2months.
•Examinee mustnothaveahistoryofECTorradiation totheCNS.
•Examinee mustnotbe(currently orinthepast)diagnosed withapsychotic disorder, orcurrently
diagnosed withamooddisorder (however, MajorDepressive Disorder inremission orwithno
Title:ClinicalInvestigation Plan Author:LauraKlaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version: 2.0 Date:2019-02-18 Status:Approved Page:23of35
IRBMANAGER PI[INVESTIGATOR_8571] —QIPROJECT
PhilipsResearchP1—I ILIPS
currentepi[INVESTIGATOR_1865], andDysthymic andAdjustment Disorders, areacceptable) orananxietydisorder
withsymptoms significant enoughtointerfere withoptimaltestperformance.
•Autoimmune disorder(e.g.,LUPUS, MultipleSclerosis)
•Examinee mustnotbecurrently diagnosed withsubstance abuseordependence, orhavecarried
anysubstance abuseordependence diagnosis inthepastyear(>1yearinremission diagnoses
areOk).Longtermalcoholabusersareexcluded aswell(e.g.,abusedsubstance formorethan10
years)
•AnyhistoryofAutismSpectrum Disorder orIntellectual Disability.
•Theexaminee mustnotbecurrently takingmedication thatmightimpacttestperformance (e.g.,
anti-convulsants, antipsychotics, benzodiazepi[INVESTIGATOR_1651], psychostimulants, opi[INVESTIGATOR_232000],tricyclic
antidepressants, somenorepi[INVESTIGATOR_5608]). Mostantihypertensive medications
andstatinsareacceptable.
•Ifpreviously diagnosed withanyphysical condition orillnessthatmightdepresstestperformance,
illnessmustnotinterfere withnormalcognitive functioning atwork,school,ADLs,etc.Diabetes,
hypothyroidism, andhypertension areacceptable ifcontrolled.
•Exclude primarily nonverbal oruncommunicative. Mustnothaveadiagnosis ofaphasia.
•Examinees shouldnothavereceived neuropsychological testingalthough previous MMSEtesting
isallowed ifmorethan6monthsprior
•Examinee mustnotbeseekingmedicaldiagnostic procedures forcognitive difficulties froma
medicalprofessional.
•Non-valid healthinsurance in[LOCATION_003].
Criteriaandprocedures forsubjectwithdrawal ordiscontinuation
Subjects willbeenrolledwhentheinclusion criteriaandexclusion criteriaaremetandwhenthe
subjecthassignedtheinformed consentform.
Subjects canleavethestudyatanytimeforanyreason iftheywishtodosowithoutany
consequences.
Ifoneofthefollowing criteriaisfulfilled,theparticipation ofasubjecttothestudyisterminated:
•Subjectindicates thathewishestoleavethestudy
•Subject isnotabletousetheiPadPro(testdatawillnotbedestroyed butflaggedasinvalid)
•Subjectdoesnotmeetinclusion/exclusion criteriaanymore
•Theinvestigator candecidetowithdraw asubjectfromthestudyformedicalreasons.
Thesesubjects needtobereplaced according tothesampling planiftestdataofasubjectare
destroyed ortestdataarenotcomplete duetostudytermination.
Thepointofenrolment isthetimeatwhich,following recruitment, asubjectsignsanddatesthe
informed consentform.Thefirstsubjectisexpected tobeenrolled inMarch152019. TheClinical
Investigation isexpected totake6months.
Theduration ofeachassessment is90minutes.
Inthisclinicalinvestigation, thecompany thatwillrecruittheparticipants willaccountforanexpected
dropoutrateof20%.
6.4Procedures
Specimen Banking (savinghumanfluidortissueforfutureresearch)
Notapplicable—this isahumanstudywithoutspecimen banking.
Clinicalprocedures
Participants included ingroupA-Dwillbeinvitedforanassessment ontwodifferenttimepoints
(phases). Bothassessments willtakeapproximately 1.5hours.Aftersigninganinformed consent,
participants willreceiveeitheralldigitalorallpaper-pencil cognitive testsinphase 1andeitherall
digitalorallpaper-pencil cognitive testsinphase2,depending ongroupassignment. Seefigure 1for
Htle:ClinicalInvestigation Plan Company Restricted
DodD:ICBE-2-[ZIP_CODE] Jsion: 2.0 Status:Approved Page:24of35
IRBMANAGER PI[INVESTIGATOR_8571] —QIPROJECTAuthor:LauraKlaming
Date:2019-02-18
PhilipsResearchP1—IILIPS
anoverview ofthestudydesign.Participants included ingroupEofthestudy(seefigure1)willonly
receiveoneassessment (alldigitalcognitive tests).50%ofgroupEwillbeenrolled inphaseIandthe
other50%ofgroupEwillbeenrolled inphase2.
Thisassessment willtakeapproximately 1.5hours.Allparticipants willbeaskedtocomplete aMoCA
screener. Thestudywillbeconcluded wheneachcellofthedesign(groupA-E)meetsitsrequired
samplesizewithparticipants thatmeettheinclusion criteriaandcompleted thetestsspecified fortheir
group.
Sponsor activities
Philips,asthesponsor, willberesponsible for:
•InternalEthicsapproval
•Providing Principal Investigator
•StudyDesign
•Monitoring
•Datastorage
•Dataintegritycheck
•Dataanalysis
•Report
Supplier (CRCactivities):
•Selection ofroomsfordatacollection
•Selection ofpsychometrists
•IRBapproval
•Recruitment ofparticipants
•Datacollection
6.5Monitoring plan
Inaccordance with21CFR312.56,theclinicalmonitor willperiodically inspectallCRFs,study
documents andresearch facilitiesassociated withthisstudyatmutually convenient timesduringand
aftercompletion ofthestudy.Asrequired by[CONTACT_232054] (Responsibilities ofSponsors and
Investigators), themonitoring visitsprovidetheSponsor withtheopportunity toevaluate theprogress
ofthestudy;verifytheaccuracy andcompleteness ofCRFs;ensurethatallprotocolrequirements,
applicable FDAregulations, andinvestigator’s obligations arebeingfulfilled;andresolveany
inconsistencies inthestudyrecords. Thisincludes inspection ofalldocuments andrecordsthatare
required tobemaintained by[CONTACT_36705].. Thenamesandidentities ofallresearch subjects willbe
keptinstrictconfidence andwillnotappearonCRFsorotherrecordsprovided toorretained by[CONTACT_75376]. Theregulations alsorequiretheinvestigator toallowauthorized representatives oftheFDA
toinspectandmakecopi[INVESTIGATOR_232009].Thenamesandidentities ofthesubjects neednotbe
divulged totheSponsor; however, therecordsmustnevertheless beinspected. Thiscanbe
accomplished by[CONTACT_232055]’s nameandreplacing thenamewiththesubject’s studyID
number. Iftheserequirements areinconflictwithlocalregulatory restrictions orinstitutional
requirements, theinvestigator mustinformtheSponsor oftheserestrictions priortoinitiation ofthe
study.
SeetheMonitoring Planforadescription ofhowmonitoring oftheconductandprogress oftheclinical
studywillbeconducted. Monitoring ofthestudywillbeconducted by[CONTACT_232056](CT18_Monitoring_Plan).
7STATISTICAL CONSIDERATIONS
Statistical design,analyses andpowerconsiderations
Belowwedescribe theplannedanalyses foreachaimandhypothesis. Thetestsarescoredby[CONTACT_232057](with30%overlap)andinter-rater agreement isassessed priortoproceeding withthefollowing
analyses. Allcorrelations mentioned belowarePearson correlations. Retestcorrelations arecorrected
forthevariability ofthenormative sample(Allen&Yen,2002;Magnusson, 1967).Correlation between
paperandpencilmeasures arecorrected formeasurement error(Padilla &Veprinsky, 2012).Inour
poweranalyses weassumeanalphaof.05.
Title:ClinicalInvestigation Plan Author:LauraKiaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version:2.0 Date:2019-02-18 Status:Approved Page:25of35
IRBMANAGER PI[INVESTIGATOR_8571] —QIPROJECT
PhilipsResearchP1—IILIPS
AimIcomparison ofpsychometrics.
Hypothesis A:Digitalandpaper-pencil testscoresarecomparable.
Foreachtest,wewillfirstcompute age-only referenced scoresfordigitalandpaper-pencil version
separately. Referenced scoresarecomputed basedontheregression basednorms(procedure
described belowunderaim3)andarerepresented asz-scores indicating aparticipant’s deviation from
whatwouldbeexpected basedonthenormsampleforaparticipant withidenticaldemographic
characteristics. Wethencompute thecorrelation between digitalandpaper-pencil referenced scores
withinparticipants ingroupAandB(whicharethegroupsinwhichparticipants completed bothdigital
andpaper-pencil versions ofthetests),whichneedstober>.6tobeconsidered comparable. Our
plannedsamplesizeallowsustodetectacorrelation ofr>.2with80%power.Wealsoperforman
equivalence testforeachtest,comparing thedistribution ofdigitalnormedscoreswithpaper-pencil
normedscores,usingatwo-one-sided-t-test approach (TOST;Schuirmann, 1987),withequivalence
boundsof±.3sd,whichwehave99%powertodetect.Ourplannedsamplesizewouldallowusto
detectequivalence withboundsofatleast±.21with80%power.
Hypothesis B:Test-retest reliability iscomparable.
Test-retest reliability willbetestedby[CONTACT_232058] 1andphase2(groupC)andcomparing thistothecorrelation between thepaper-pencil tests
inphase 1andphase2(groupD).Hightest-retest correlations areexpected (r>0.7),exceptforthe
ROCFTcopycondition, sincethescoresofthiscondition generally showamoderate ceilingeffect.
TheplannedsamplesizeforgroupCandgroupDeachyield80%powertodetectr>.37.
Hypothesis C:Construct validityiscomparable.
Construct validitywillbeinvestigated by[CONTACT_232059] (CFA),onefor
eachgroup(digitalvs.paper-pencil). Weexpecttoseethatthefactorstructure thatfitsthepaper-
pencildata(phase1,groupB&D)well,willalsofitthedigitaldata(phase1,groupA&C)well.
Assuming thatatmosttwovariables pertestareincluded intheCFA,thesubject-to-variable ratiois
near10:1foreachCFA.
Aim2Agreement between algorithm andmanualscoring
Hypothesis D:Thescore(s) provided by[CONTACT_232060](>.8)tothescoreprovided by[CONTACT_232047].
Foreachtestwithalgorithmic scoring,agreement withmanualscoring willbetestedusingthetwo-
one-sided t-testsapproach (TOST;Schuirmann, 1987)ontheaveragecorrelation between the
algorithm andeachraterontheonehandandtheaverage correlation between theraterandeach
otherraterontheother.Beforesubmitting thecorrelations totheTOSTanalysis, weapplyFisher’sr
to-ztransformation. Wewilluseequivalence boundsofr±.1asastringent criterion ofpractical
equivalence, although wenotethatanycorrelation >.8provides sufficient supportforourclaimgiven
thatthealgorithms mayactuallybemoreanimprovement relativetomanualscoring.
Weusedasimulation approach toestimate thesamplesizeofratersneededtohave80%powerto
detectequivalence inagreement usingTOST.Thisapproach isdescribed indetailinTechnical Note
PR-TN2018/0033 (Dotsch &Klaming, 2018).FortheROCFT, thesimulation approach hasresulted in
therecommendation thatsixraterswillberequired toscorearandomsampleof100drawings from
thetestinordertoderiveatleast80%powerwithstringent equivalence boundsbackingastrong
claimofequivalence between ratersandalgorithm. Weassumed thatfortheCDTasimilarnumberof
raterswouldbesufficient, giventhatscoringofdrawings frombothtestshavegenerally highinter-rater
agreement.
Aim3.Estimate regression-based normsandreliablechangeindices
Title:ClinicalInvestigation Plan Author:LauraKlaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version:2.0 Date:2019-02-18 Status:Approved Page:26of35
IRBMANAGER PI[INVESTIGATOR_8571] —QIPROJECT
PhilipsResearchP1—IILIPS
Thedatacollected canbeusedtoestablish regression-based norms.250(upto300)participants
(groupA&C,phase 1andgroupE)willbeincluded inthenormgroup.Thesenormscanbeusedfor
theIntelliSpace Cognition toolandmaybeupdatedatalaterpointintime.
Reference scores(forage,educational level,gender,andethnicity) willbegenerated usinglinear
regression techniques. Wewilladditionally estimate regression basedreliablechangeindices.
Aim4.Estimate factorloadings forcognitive modeldescribing
Wehavedeveloped amodelofcognitive functioning usingthelatentvariablepartofstructural
equation modelling (whichisidentical totheCFAdescribed above).WewillfittheISCmodelof
cognitive functioning onthedigitaltestdatafromGroupA,C,andE,yieldingasampleof250(upto
300)participants fortheCFA,furtherincreasing thesubject-to-variable ratioto—12:1.
Samplesize
ThestudywillincludeatotalofN=400(uptoN450)healthyindividuals, withoutaccounting fordrop
out(seeFigure 1forthedesign);Thetestswillbescoredby[CONTACT_232023]-trained raters.Moreover, to
compute theinter-rater agreement between scoringalgorithms andmanualscoringweneedsix
additional well-trained raters.
Significance andpower
Pleaseseeabovedescription.
Expected drop-out rates
Theexpected drop-out rateis20%.Thecompany thatwillrecruittheparticipants willoversample by
20%toaccountforthedrop-out rate,resulting in80additional participants recruited inaddition tothe
400neededforthefulldesign.
Passlfail criteria
Pleaseseeabovedescription.
Interimanalysis
Notapplicable.
Termination ofentirestudyonstatistical grounds
Thestudywillbeterminated ifasamplesizeofN=400withthespecified distribution acrossage,
gender,education level,andethnicitycannotbeachieved.
8DATAMANAGEMENT
Datawilleitherbecaptured onpaperandlatertranscribed totheelectronic casereportforms(eCRF5)
ordirectlyreported intotheeCRFsatthetimeofprocedure completion. Digitaltestdatawillbe
captured withourdigitalsoftware toolsinthecloud.Ultimately, Philipswillhandlealldatainthe
Datatrak system.
Researchers willbetrainedonthedevicesandthespecificdatamanagement forthestudypriortothe
startofthestudy.Theresearchers willbeprovided usernames andpasswords uniquetoeach
researcher.
Papersourcedocumentation (firstlydocumenting dataonpaperwithlatertranscription intothe
eCRFs)shallbeusedfordatametrics(e.g.,informed consent, randomization, safetymetricscaptured
elsewhere, eligibility metrics,standard Siteforms,etc.).
Documents thatmaybeusedtocapturesourcedataonpaperinclude,butarenotlimitedto:standard
Siteforms,studydiaries,oranyoftheDocument Template forms,etc.Eachpaperformshallhave
adequate study/Site andsubjectidentifiers andmustbeandremainlegible. Ablueorblackpen
shouldbeusedtodocument data.Apencilshouldneverbeused.
Title:ClinicalInvestigation Plan Author:LauraKiaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version:2.0 Date:2019-02-18 Status:Approved Page:27of35
IRBMANAGER PI[INVESTIGATOR_8571]—01PROJECT
PhilipsResearchP1—IILIPS
Researchers willbeprovided withtherequired formsby[CONTACT_191731],apapertemplate ofthefieldsrequired
tocomplete theeCRF.Thesewillallowresearchers toidentifywhichdatapointswillrequire
documentation acrossthestudy.
Procedures
1.Thesupplier willhaveacompliant procedure toassurethedatacollection iscollected according
theregulations andthatthedataisstoredandcannotbealtered.
2.Thedatawillbecollected by[CONTACT_232061].
3.Digitaldatawillbestoredinthe(Philips) cloudwhichisHIPAAandpart11compliant.
4.Datawillbereviewed andcleaned by[CONTACT_191731].
5.PhilipswillhandlealldataintheDatatrak system.
AllsystemsthatarebeingusedareCFRpart11compliant.
Dataretention
PleaseseePlAsupport document foradetailedoverview ofdatacollected andtheirretention time.
Allrecordsanddocuments pertaining tothestudyincluding, butnotlimitedto,dataandsource
documents, willbemaintained by[CONTACT_232062]15years.Inordertoavoidanypossible
errors,theresearcher willcontact[CONTACT_232063].The
researchers willpromptly notifytheSponsor intheeventofaccidental lossordestruction ofanystudy
records.
However thedigitaldatagenerated by[CONTACT_232064](seestudyobjectives). Theserecords willnotberelatedtoanypatientID,
butwillbedelivered aspartoftheISCproducttofuturecustomers oncetheproductisonthemarket.
QualityAssurance
TheSponsor oritsdesignee willimplement stepstomaintain qualitycontrol(QC)andquality
assurance (QA)toensurethatthestudyisconducted anddataaregenerated, documented, and
reported incompliance withtheprotocol, goodclinicalpractice, andapplicable regulatory
requirements. Thiswillbecompleted by[CONTACT_232065].
Regularmonitoring andanindependent audit,ifconducted, mustbeperformed according toICH
GCP.QCprocedures willbeimplemented beginning thestudydataQCcheckswillbeperformed. Any
missingdataordataanomalies willbecommunicated totheresearchers forclarification/resolution. It
istheresponsibility oftheresearcher torespond toalleditschecksandqueries.Storeddataaswellas
alldatamodifications tostoreddatawillbedocumented by[CONTACT_232066].
Following writtenprocedures, themonitors willverifythattheclinicaltrialisconducted anddataare
generated, recorded, andreported incompliance withtheprotocol, GOP,andtheapplicable regulatory
requirements.
Theresearchers willprovidedirectaccesstoalltrialrelatedsites,sourcedata/documents, andreports
forthepurpose ofmonitoring andauditing by[CONTACT_177262], andinspection by[CONTACT_232067]. Inaddition, postdatasubmission, Philips(orcontracted) Monitors, ProjectStatistician,
and/ortheDataManagement groupwillremotely reviewdatagenerated atdifferent timepointsduring
thestudy.Dataqueries willbegenerated toresolveanydiscrepancies orconcerns.
9AMENDMENTS
Anychanges totheclinicalstudyprotocolafterinitiallOBEapproval aredocumented asprotocol
amendments. AfterlOBEapproval, andpriortoexecution atthestudysite,theamendment willbe:
•submitted andapproved by[CONTACT_232068]
•signedby[CONTACT_29256](s)
10DEVIATIONS
Protocoldeviations areanyalteration ordeviation fromthelOBE-approved research planasdefined in
thestudyprotocol. Thisincludesequipment failuresduringstudyprocedures. Theresearcher will
[tIe:ClinicalInvestigation Plan Author:LauraKlaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version: 2.0 Date:2019-02-18 Status:ApprovedIPage:28of35
IRBMANAGER PI[INVESTIGATOR_8571] —QIPROJECT
PhilipsResearchP1—IILIPS
deviatefromtheprotocolwhenever necessary toprotecttheparticipant’s health,rightsorwelfareand
thesetypesofdeviations willbereported toICBEandtheexternal IRBassoonaspossible. Major
deviations mustbereported toICBEandtheIRBassoonaspossible. Innon-urgent/emergent
situations, theresearcher willobtainICBE-approval fortheplanneddeviation inadvance ofperforming
thechanged activity.
Iftheresearcher anticipates thattherewillbefuturerequests forthesamedeviation, thentheprotocol
willbeamended (andsuchamendments mustbeapproved by[CONTACT_232069]).Aminordeviation
issomething thatdoesnotcauseharmorhavethepotential tocauseharmtotheparticipant, and
doesnotimpacttheintegrity ofthestudy.Theseshallbedocumented inthestudyfileanduploaded
toICBEfortheirawareness. Otherreasons foramendment requests includeaddingastudysite,
increasing thenumberofresearch participants, andextending thetimetoperformthestudy.Ifthe
studyobjectives andprocedure orcohortchanges orthestudychanges fromnon-medical tomedical,
thisgenerates anewstudy(notanamendment).
Corrective andpreventive actionsandprincipal disqualification criteria
Whennecessary, therewillbegivenadditional trainingtotheresearchers toconductthestudy
according toprotocol.
11DEVICE ACCOUNTABILITY
Theprocedures fortheaccountability ofinvestigational devicesareinaccordance withtheGuidance.
Theaccesstoinvestigational devices willbecontrolled andtheinvestigational devices willonlybe
usedintheclinicalinvestigation andaccording totheCIP.
Thesponsor shallkeeprecordstodocument thephysical locationofallinvestigational devicesfrom
shipment ofinvestigational devicestotheinvestigation sitesuntilreturnordisposal. Thisrecordwillbe
basedonValidation ISO —devicelist.
Theprincipal investigator [INVESTIGATOR_232010],use,
returnanddisposal oftheinvestigational devices. Thisisalldocumented intheValidation ISO —
devicelist.Thisrecordshallinclude (ifapplicable):
•thedateofreceipt,
•identification ofeachinvestigational device(batchnumber/serial numberoruniquecode),
•theexpi[INVESTIGATOR_232011],ifapplicable,
•thedateordatesofuse,
•subjectidentification,
•ateonwhichtheinvestigational devicewasreturned/explanted fromsubject, ifapplicable, and
•thedateofreturnofunused,expi[INVESTIGATOR_232012], ifapplicable.
12STATEMENTS OFCOMPLIANCE
Theclinicalinvestigation willbeconducted according totheprinciples oftheDeclaration ofHelsinki
andotherguidelines, regulations andActs.
Theclinicalinvestigation shallnotbeginuntiltherequiredapproval/favorable opi[INVESTIGATOR_232013]. Anyadditional requirements imposed by[CONTACT_232070].
Compensation forinjury
General liabilityinsurance isarranged by[CONTACT_232071].
Title:ClinicalInvestigation Plan Author:LauraKlaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version:2.0 Date:2019-02-18 Status:Approved Page:29of35
IRBMANAGER PI[INVESTIGATOR_8571] —QIPROJECT
PhilipsResearchP1—IILIPS
Sponsorwishestoobtaindispensation fromstatutory obligation toprovideinsurance, because
participating inthestudyiswithoutrisks.Areasoned request willbemadetoaccredited ECandthis
dispensation willbementioned here.
13INFORMED CONSENT PROCESS
Selectallthatapply:
Therequirement forinformed consenthasbeenwaived(i.e.,notrequired
by[CONTACT_232072]/REC/METC). Uploadwaiver ifavailable.
Writteninformed consent willbeobtained fromadultparticipants
Assent willbeobtained fromchildren/minors
Parental permission willbeobtained whenchildrenareparticipating
Surrogate consent willbeobtained whenparticipants lackdecisional
capacity
Deferred consent willbeobtained [e.g.,emergency research]
DClick-through consent willbeobtained [Internet/app-based research]
Impliedconsent [i.e.,consent through actionsuchastakingatest]
13.1ConsentProcess(SeeSection13.3reAssent &Permission)
Studyparticipation isvoluntary. Potential subjects, aregiventhemostcurrentICBE/IRB approved
consentformtoread.Theywillbeprovided ampletime(+1week)forreviewandanopportunity toask
questions aboutthestudy.Theinformed consentformwillbeprovided by[CONTACT_232073]. Iftheyagreetoparticipate, theCRCwillschedule theparticipant for
participantion andtheywillsigntheconsentformbeforethestartofthestudy.Theywillbegivena
copyofthesigneddocument fortheirrecords. Eachoftheseactions/steps willbedocumented. Only
afterInformed Consenthasbeenobtained, maytheremaining studyprocedures begin.
13.2NewInformation abouttheStudy
Anynewinformation aboutthestudythatmayaffectaconsented subject’s decision tobeinthestudy
(e.g.,changed procedures, safety,etc.),willbecommunicated inatimelymanner. Depending onthe
natureofthenewinformation, subjects whohavecompleted thestudymayormaynotbeinformed,
documenting thedecision andjustification aswellasanyactivities forinforming completed subjects.
Additionally, theapproving IRBwillalsobeinformed. Thecurrently approved Consent Formwillbe
updatedandsubmitted totheICBEandapproving IRBforreviewandapproval. Activesubjects willbe
re-consented, following theaboveprocess, withthenewly-approved consentform.
13.3InabilitytoProvideConsent (children oradults)
N/A
14ADVERSE EVENTS ANDDEVICE DEFICIENCIES
Definitions
Title:ClinicalInvestigation Plan Author:LauraKlaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version: 2.0 Date:2019-02-18 Status:Approved Page:30of35
IRBMANAGER PI[INVESTIGATOR_8571]—01PROJECT
PhilipsResearchPP—IILIPS
Adverse eventsandadverse deviceeffects,devicedeficiencies andseriousadverse eventsand
seriousadverse effectsand,unanticipated seriousadverse deviceeffectsaredefined inthetable
below:
Definition Description
Adverse Event Anyuntoward medicaloccurrence, unintended diseaseorinjury,oruntoward clinicalsigns
(AE) (including abnormal laboratory findings) insubjects, usersorotherpersons,whetherornot
relatedtotheinvestigational medicaldevice
NOTE 1Thisdefinition includeseventsrelatedtotheinvestigational medicaldeviceorthe
comparator.
NOTE2Thisdefinition includeseventsrelatedtotheprocedures involved.
NOTE3Forusersorotherpersons, thisdefinition isrestricted toeventsrelatedto
investigational medicaldevices.
Adverse Adverseeventrelatedtotheuseofaninvestigational medicaldevice
DeviceEffectNOTE 1Thisdefinition includeseventsrelatedtotheinvestigational medicaldeviceorthe
“comparator.
NOTE2Thisdefinition includeseventsrelatedtotheprocedures involved.
NOTE3Forusersorotherpersons, thisdefinition isrestricted toeventsrelatedto
investigational medicaldevices.
SeriousAdverseeventthat
Adverse Eventa)ledtodeath,
‘SAE’b)ledtoseriousdeterioration inthehealthofthesubject,thateitherresulted in
‘‘ 1)alife-threatening illnessorinjury,or
2)apermanent impairment ofabodystructure orabodyfunction, or
3)in-patient orprolonged hospi[INVESTIGATOR_059], or
4)medicalorsurgicalintervention topreventlife-threatening illnessorinjuryor
permanent impairment toabodystructure orabodyfunction,
c)ledtofoetaldistress,foetaldeathoracongenital abnormality orbirthdefect
NOTEPlannedhospi[INVESTIGATOR_231998]-existing condition, oraprocedure required by[CONTACT_232074],withoutserious
deterioration inhealth,isnotconsidered aseriousadverseevent.
Serious Adverse deviceeffectthathasresulted inanyoftheconsequences characteristic ofa
Adverse seriousadverseeventorthatmighthaveledtoanyoftheseconsequences ifsuitableaction
DeviceEffect hadnotbeentakenorintervention hadnotbeenmadeorifcircumstances hadbeenless
(SADE)
Unanticipated . . .
.Seriousadversedeviceeffectwhichby[CONTACT_232075],incidence, severityoroutcome hasnotAdverse Devicebeenidentified inthecurrentversionoftheriskanalysisreport
NOTEAnticipated seriousadversedeviceeffect(ASADE) isaneffectwhichby[CONTACT_232075],
incidence, severityoroutcome hasbeenidentified intheriskanalysis report.
Reportability
Alladverse eventsshallbereported totheStudyManager. ADEs,SAEs,SADEsand[LOCATION_003]DEs shall
bereported totheQ&Rofficeaswell.TheDirector Q&RshallassesstheADEs,SAEs,SADEsand
[LOCATION_003]DEs forreportability toCompetent Authorities.
Reporting process
Reporting shallincludethedateoftheadverse event,research subject ID#,description oftheadverse
event,treatment, resolution, andassessment ofboththeseriousness andtherelationship tothe
investigational deviceandstudyprocedures.
Title:ClinicalInvestigation Plan Author:LauraKlaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version: 2.0 Date:2019-02-18 Status:Approved Page:31of35
IRBMANAGER PI[INVESTIGATOR_8571] —QIPROJECT
PhilipsResearchP1—I ILIPS
Timelines
Thetimeperiodinwhichtheprincipal investigator [INVESTIGATOR_232014],whereappropriate, toECsandtheregulatory authority, andthe
detailsoftheprocess forreporting devicedeficiencies, aredetailed inthetablebelow.
Category ReporttoStudyManager ReporttoAccredited Ethics ReporttoQ&Roffice
Committee
by [CONTACT_232076] [INVESTIGATOR_232015]’s ClinicalInvestigation Report
(AE) Sponsor
Periodiccollection by
[CONTACT_232077](ADE) Reporting timelines
or
<24hrfollowing instructions by
[CONTACT_232078]
(SAE) Immediate, <24hr or Immediate, <24hr
<24hrfollowing instructions by
[CONTACT_232079], <48hrs
DeviceEffect
(SADE)
Unanticipated AspartofEthicsCommittee
Adverse Device Reporting timelines
Effect(UADE) or
<24hrfollowing instructions by
[CONTACT_232080]. Theonlyeventweforesee is
fatigueofparticipants thatareparticipating inourstudy.
Sincetherearenopossible adverse events,thereisnoforeseen needtocontact[CONTACT_232081]/suspend orcontinue thetrialdepending thesoftware faultandtherisksofachieving thetrial
objectives. Thereisnoriskforthesubjects evenifthedeviceisatfault.
Emergency contact[CONTACT_8972]
N/A
Information regarding theDataManagement Committee, ifestablished
N/A
Incidental Finding Reporting
AnIncidental Finding isafindingconcerning anindividual research participant thathaspotential
healthorreproductive importance andisdiscovered inthecourseofconducting research butis
beyondtheaimsofthestudy.
Allincidental findings willbedocumented inatimelymannerthroughout thestudy.Thereport
Incidental FindingReportForm(seelOBESP)willbeinthereceiptofPhilipsResearch Q&ROffice
within7business daysofwhentheresearcher firstlearnsaboutthefinding.
Title:ClinicalInvestigation Plan Author:LauraKiaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version: 2.0 Date:2019-02-18 Status:Approved Page:32of35
IRBMANAGER PI[INVESTIGATOR_8571] —QIPROJECT
PhilipsResearchP1—IILIPS
15INVESTIGATOR BROCHURE (IB)
AnlBisneededandincluded inthelOBEstudydossier.
16VULNERABLE POPULATION
According toISO14155,avulnerable subjectisanindividual whosewillingness tovolunteer ina
clinicalstudycouldbeundulyinfluenced by[CONTACT_232082], whetherjustifiedornot,ofbenefits
associated withparticipation orofretaliatory response fromseniormembers ofahierarchy incaseof
refusaltoparticipate.
None—this studyuseslivehumanparticipants butnotfromvulnerable populations
Indicatewhetheryouwillincludeanyofthefollowing (vulnerable) populations inyourstudy:
Children orviableneonate (birthtoage28days)
Cognitively impaired
LPregnant women(except[LOCATION_003])
DFetuses
Neonates ofuncertain viabilityornonviable
flPrisoners
EPoor/uninsured
Educationally disadvantaged (limitededucation, e.g.,highschooldropout)
Students (including interns,residents, fellows)
LMinorities (includes migrants, refugees)
Elderly(overage65years)
LTerminally ill
DOther(checkboxandspecifically discussbelow)
Informedconsent formwillbeprovided withdetailedinformation aboutthestudy.
Psychometrists whoareexperienced withthisagegroupwillcollectthedata.
17SUSPENSION ORPREMATURE TERMINATION
Incasethestudyisendedprematurely, theinvestigator willnotifytheIRBandtheICBEaboutthe
reasonsforthepremature termination.
Title:ClinicalInvestigation Plan Author:LauraKlaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version:2.0 Date:2019-02-18 Status:Approved Page:33of35
IRBMANAGER PI[INVESTIGATOR_8571]—01PROJECT
PhilipsResearchP1—IILIPS
Theprincipal investigator [INVESTIGATOR_232016].
Thefollowing criteriaandarrangements forsuspension orpremature termination ofthewholeclinical
investigation oroftheclinicalinvestigation inoneormoreinvestigation sitesapply:
•Philipsdecidestostopthestudy.
Incaseofsuspension orpremature termination oftheclinicalinvestigation, thefollowing requirements
applyforsubjectfollow-up.
•N/A
18PUBLICATION POLICY
Resultsofclinicalinvestigation maybesubmitted forpublication. Philipsshallregisterandreportthe
resultsofthisapplicable trialonclinicaltrials.gov.
19BIBLIOGRAPHY
Listofbibliographic references pertaining toclinicalinvestigation
Allen,M.J.,&Yen,W.M.(2002).Introduction tomeasurement theory.LongGrove, IL:Waveland
Press.
Akshoomoff, N.A.,&Stiles,J.(1995).Developmental trendsinvisuospatial analysisandplanning:
memory foracomplex figure.Neuropsychology, 9(3),378-389.
Anderson, P.,Anderson, V.,&Garth,J.(2001).Assessment anddevelopment oforganizational ability:
theReyComplex FigureOrganizational StrategyScore(RCF-OSS). TheClinicalNeuropsychologist,
15(1),81-94.
Bauer,R.M.,Iverson, G.L.,Cernich, A.N.,Binder,L.M.,Ruff,R.M.,&Naugle, R.I.(2012).
Computerized neuropsychological assessment devices: jointpositionpaperoftheAmerican Academy
ofClinicalNeuropsychology andtheNationalAcademy ofNeuropsychology. Archives ofClinical
Neuropsychology, 27,362-373.
Bennett-Levy, J.(1984).Determinants ofperformance ontheRey-Osterrieth Complex FigureTest:an
analysis, andanewtechnique forsingle-case assessment. TheBritishJournalofClinicalPsychology!
theBritishPsychological Society, 23(Pt2),109-119.
Chiulli,S.J.,Haaland, K.Y.,Larue,A.,&Garry,P.J.(1995).ImpactofageondrawingtheRey
Osterrieth figure.TheClinicalNeuropsychologist, 9(3),219-224.
Deckersbach, T.,Savage, C.R.,Henin,A.,Mataix-Cols, D.,Otto,M.W.,Wilhelm, SJenike, M.A.
(2000).Reliability andvalidityofascoringsystemformeasuring organizational approach inthe
Complex FigureTest.JournalofClinicalandExperimental Neuropsychology, 22(5),640-648.
Fortuny, L.A.,&Heaton, R.K.(1996).Standard versuscomputerized administration oftheWisconsin
CardSortingTest.TheClinicalNeuropsychologist, 10(4),419-424.
Greve,K.W.(1993).Canperseverative responses ontheWisconsin CardSortingTestbescored
accurately? Archives ofClinicalNeuropsychology, 8,511-517.
Hamby,S.L.,Wilkins,J.W.,&Barry,N.S.(1993).Organizational qualityontheRey-Osterrieth and
TaylorComplex FigureTests:anewscoringsystem.Psychological Assessment, 5(1),27-33.
Title:ClinicalInvestigation Plan Author:LauraKiaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version:2.0 Date:2019-02-18 Status:Approved Page:34of35
IRBMANAGER PI[INVESTIGATOR_8571]—01PROJECT
PhilipsResearchP1—IILIPS
Kiaming, L.,&Vlaskamp, B.N.S.(2017).Non-dominant handuseincreases completion timeonpartB
oftheTrailMakingTestbutnotonpartA.Behavior Research Methods, 1-14.
Magnusson, D.(1967).Testtheory.Reading, MA:Addison-Wesley.
TheMarkeTech group(2018).Anonlinesurveyof75US-based neurologists, conducted by[CONTACT_232083].
Miller,J.B.,&Barr,W.B.(2017).Thetechnology crisisinneuropsychology. Archives ofClinical
Neuropsychology, 1-14.
Padilla, M.A.,&Veprinsky, A.(2012).Correlation Attenuation DuetoMeasurement Error:ANew
Approach UsingtheBootstrap Procedure. Educational andPsychological Measurement, 72(5),
827—846. https://doi .org/10.1177/0013164412443963
Paolo,A.M.,Axeirod, B.N.,&Ryan,J.J.(1994).Administration accuracy oftheWisconsin Card
SortingTest.TheClinicalNeuropsychologist, 8(1),112-116.
Schatz,P.,&Browndyke, J.(2002).Applications ofcomputer-based neuropsychological assessment.
TheJournalofHeadTraumaRehabilitation, 17(5),395-410.
Shorr,J.,Delis,D.,&Massman, P.(1992).Memory fortheRey-Osterrieth Figure:perceptual
clustering, encoding, andstorage. Neuropsychology, 6,43-50.
Strauss, E.,Sherman, EMS., &Spreen,0.(2006).Acompendium ofneuropsychological tests:
administration, norms,andcommentary(3rded.).NewYork:OxfordUniversity Press.
Tien,A.Y,Spevack, TV.,Jones,D.W.,Pearlson, GD.,Schlaepfer, T.E.,&Strauss, M.E.(1996).
Computerized Wisconsin CardSortingTest:comparison withmanualadministration. Kaohsiung
JournalofMedicalSciences, 12,479-485.
Anonlinesurveyof75US-based neurologists, conducted by[CONTACT_232084],revealed that
theaverage waitingtimeforaneuropsychological evaluation is7.6weeks.
575US-based neurologists wereasked;“Forwhatpercentage ofallyourpatients doyou
currently request afullneuropsychological assessment?” Theaverage ofallresponses was
13%.Theywerethenasked,“Inanidealworldwhichpercentage ofallyourpatients would
youliketosendforafullneuropsychological assessment?” Theaverage ofallresponses
was36%.
[Endofdocument]
Title:ClinicalInvestigation Plan Author:LauraKlaming Company Restricted
DodD:ICBE-2-[ZIP_CODE] Version: 2.0 Date:2019-02-18 Status:Approved Page:35of35
IRBMANAGER PI[INVESTIGATOR_8571]—01PROJECT
II
C.00000a
V
Ia
-.1.1.1.I.1
Sa
V
—Fl.1.1.10a
j
C000.1.1a
j.000ev-S
a
-.1.1.1.10a
V
Ia
[IP_ADDRESS]
oeeeeea
V
Ia
J
Ia
V
-.[IP_ADDRESS].1a
1.1.I.I.I.1
a
aaa
je.e.c.a
.1.1.100a
V
I
II
I;un
Marginals Target
Male female White Black Hispanic Other <12years 12years >12years
50-54 50 25 25 33 7 7 3 5 15 30
55-59 50 25 25 35 6 6 3 5 16 29
60-64 50 25 25 36 6 5 3 5 16 29
65-69 50 25 25 37 5 5 3 5 15 30
70-74 50 25 25 37 6 5 2 6 15 29
75-80 50 25 25 40 4 4 2 9 18 23
I aC NftNH4141414141
I;mmmmm
—H.1.1.1 —[PHONE_4867]
I
B
iiiiiiI
4tses.. B
%NflN a1311111 1I111111 1
111111NN B
I—.1flfl1 H4141414141I
ease.
I m‘-—‘I..——‘‘[PHONE_4867]
I
I
I‘q.fl’;I 9
I
j:BBRRS a
—Nfl_as B914141414141 iiI
Jmmmmmfl
abmmmmm
I.fl___•4 aI
IBBBIB
I:ini